Ross Selby

Ross Selby

Ross Selby, MRPharmS, Bluebird bio UK’s Access, Value and Evidence Strategy Lead

  • Ross Selby 3x2
    HSJ Partners

    Gene Therapy – will the NHS lead or follow?


    In a four-part series, Bluebirdbio is exploring how the NHS can embrace the power of gene therapy as a treatment for rare diseases in the UK, including some of the systemic changes that will be needed. In this fourth and last column, Ross Selby, MRPharmS, Bluebirdbio UK’s Access, Value and ...